Literature DB >> 31615823

Responsible use of rifampin in Canada is threatened by irresponsible shortages.

Adam R Houston1, Ryan Cooper2, Faiz Ahmad Khan3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31615823      PMCID: PMC6791796          DOI: 10.1503/cmaj.73160

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Responsible use of rifampin for the treatment of latent tuberculosis infection.

Authors:  Jane Batt; Kamran Khan
Journal:  CMAJ       Date:  2019-06-24       Impact factor: 8.262

2.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

3.  Cost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort Study.

Authors:  James C Scott; Neha Shah; Travis Porco; Jennifer Flood
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.